Advances in combination therapy of ombitasvir and dasabuvir for chronic hepatitis C virus genotype 1 infection

VernacularTitle: 奥比帕利联合达塞布韦治疗基因1型丙型肝炎病毒感染患者的进展
Author: Huibin NING ¹ ; Junping LIU ; Erhui XIAO ; Kuan LI ; Jia SHANG
Author Information

1. Department of Infectious Disease, Henan Provincial People’s Hospital, Zhengzhou 450003, China
Publication Type:Review
Keywords: Hepatitis C virus; Direct-acting antiviral agents; Therapy
From: Chinese Journal of Hepatology 2018;26(9):710-713
CountryChina
Language:Chinese
Abstract: Since 2014, the United States and Europe has approved all oral, interferon free- regimens that combine with direct-acting antiviral agents. Hence, the sustained virological response rate of patients with chronic HCV genotype 1 infection has improved over 90%, and the treatment modalities has introduced a new era. These drugs, ombitasvir and dasabuvir, received customary authorization of Food and Drug Administration in 2015 and are the first combined direct-acting antiviral agents for treating HCV genotype 1 infection. It has superior application prospects in China because of its high-sustained virological response rate and safety profile. This article reviews the pharmacokinetics, drug interactions, efficacy and safety of this therapeutic regimen.